Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

neoantigen DNA-based pancreatic cancer vaccine

A personalized, polyepitope DNA vaccine composed of a DNA plasmid encoding multiple, highly immunogenic tumor associated antigens (TAAs) that are specifically expressed by a patient's pancreatic cancer cells, including personalized epitopes of the TAA mesothelin, with potential immunostimulatory and antineoplastic activities. Upon intramuscular administration and electroporation of the neoantigen DNA-based pancreatic cancer vaccine, the expressed TAAs induce a specific cytotoxic T-lymphocyte (CTL) immune response against tumor cells expressing the neoantigens.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:neoantigen DNA pancreatic cancer vaccine
personalized neoantigen DNA pancreatic cancer vaccine
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search